佳醫 4104.TW Overview
4104
佳醫
0.12%
(0.00)
4104 AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
4104 Current Performance
-0.12%
佳醫
-0.72%
Avg of Sector
-0.90%
TAIEX
4104 Key Information
4104 Revenue by Segments
Browsing restrictions can be lifted for a fee.
4104 Net Income
Browsing restrictions can be lifted for a fee.
4104 Cash Flow
Browsing restrictions can be lifted for a fee.
4104 Profit Margin
Browsing restrictions can be lifted for a fee.
4104 PE Ratio River
Browsing restrictions can be lifted for a fee.
4104 Profile
Excelsior Medical Co., Ltd. distributes medical related systems in Taiwan, China, Japan, Korea, Malaysia, and the Philippines. The company offers equipment for hemodialysis, regular drug used in the medical institution, surgical equipment, and medical assistant electronics; and cosmetic equipment. It also provides medical administration services for single department. The company was founded in 1988 and is based in New Taipei City, Taiwan.
4104 FAQ
When is 4104's latest earnings report released?
The most recent financial report for 佳醫 (4104) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4104's short-term business performance and financial health. For the latest updates on 4104's earnings releases, visit this page regularly.
Where does 4104 fall in the P/E River chart?
According to historical valuation range analysis, 佳醫 (4104)'s current price-to-earnings (P/E) ratio is 11.99, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of 4104?
According to the latest financial report, 佳醫 (4104) reported an Operating Profit of 181.2M with an Operating Margin of 8.43% this period, representing a growth of 9.47% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is 4104's revenue growth?
In the latest financial report, 佳醫 (4104) announced revenue of 2.15B, with a Year-Over-Year growth rate of 5.25%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does 4104 have?
At the end of the period, 佳醫 (4104) held Total Cash and Cash Equivalents of 2.8B, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does 4104 go with three margins increasing?
In the latest report, 佳醫 (4104) achieved the “three margins increasing” benchmark, with a gross margin of 21.21%%, operating margin of 8.43%%, and net margin of 11.18%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4104's profit trajectory and future growth potential.
What is the FCF of 4104?
佳醫 (4104)'s Free Cash Flow (FCF) for the period is -123.89M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 191.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.